Matthias Aizenberg

Matthias Aizenberg

Healthcare Innovation Consultant
Matthias Aizenberg is a seasoned expert in the Healthcare industry. He explores digital health, clinical processes, and healthcare management strategies. Matthias has a deep interest in pharmaceutical and healthcare innovation and is a well-trusted resource for biopharma professionals.
Can This New Microscopy Technique Revolutionize Cancer Metabolism Research?
Research & Development Can This New Microscopy Technique Revolutionize Cancer Metabolism Research?

Researchers at the University of Kentucky have pioneered a groundbreaking microscopy technique that may offer an affordable and effective way to study cancer cell metabolism. This innovative method, which focuses on observing metabolic reprogramming within cancer cells, has the potential to

New Study Debunks Myth Linking Sickle Cell Trait to Sudden Death
Research & Development New Study Debunks Myth Linking Sickle Cell Trait to Sudden Death

A recent study published in the American Society of Hematology's journal, Blood, has dispelled the long-held belief that sickle cell trait (SCT) can lead to sudden death, particularly under conditions of physical exertion. This misconception has disproportionately affected Black males with SCT,

FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain
Research & Development FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain

On Thursday, the Food and Drug Administration approved Journavx, a highly anticipated non-opioid pain medication developed by Vertex Pharmaceuticals, marking a significant milestone in the effort to shift pain treatment away from opioids. This new drug has been initially approved to treat acute

Is T-VEC an Effective Neoadjuvant Therapy for Basal Cell Carcinoma?
Research & Development Is T-VEC an Effective Neoadjuvant Therapy for Basal Cell Carcinoma?

Basal cell carcinoma (BCC) is the most common cancer worldwide, with its incidence doubling over the past 20 years. Traditional treatments, primarily surgical excision, come with a recurrence risk and potential complications. This article explores the potential of Talimogene laherparepvec (T-VEC),

Can New Drug Regimens Really Eliminate Drug-Resistant TB?
Research & Development Can New Drug Regimens Really Eliminate Drug-Resistant TB?

Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant challenge to global health. Recent advancements in TB treatment, particularly for drug-resistant forms, offer new hope. This article explores the potential of new drug

MyProstateScore 2.0: A Breakthrough in Non-Invasive Prostate Cancer Screening
Research & Development MyProstateScore 2.0: A Breakthrough in Non-Invasive Prostate Cancer Screening

Prostate cancer screening has long relied on blood tests, MRIs, and biopsies, each carrying its own set of drawbacks, such as causing discomfort and leading to the overdiagnosis of low-grade cancers that might not pose significant health risks. These traditional approaches, while effective in

How Will Tecan's Veya Revolutionize Laboratory Automation?
Tech & Innovation How Will Tecan's Veya Revolutionize Laboratory Automation?

The laboratories of today face numerous challenges that call for heightened efficiency, accuracy, and streamlined workflows, creating a pressing need for reliable automation solutions. Responding to these demands, Tecan has introduced Veya™, a cutting-edge liquid handling platform designed to

Navigating Funding Challenges for Behavioral Health Startups
Tech & Innovation Navigating Funding Challenges for Behavioral Health Startups

The current landscape of behavioral health startups is marked by a competitive funding environment. Companies in this sector face numerous challenges as they strive to secure capital, navigate investment trends, and differentiate themselves in a crowded market. This article explores these dynamics,

Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?
Research & Development Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?

The potential breakthrough in treating liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) has come from a recent study by Akero Therapeutics. Efruxifermin, an experimental drug, has shown significant promise in reversing liver damage in patients suffering from this

Can Medical Cannabis Improve Symptoms of Late-Stage Dementia?
Research & Development Can Medical Cannabis Improve Symptoms of Late-Stage Dementia?

The University of Kentucky (UK) researchers are currently engaged in a groundbreaking clinical trial aimed at exploring the potential benefits of medical cannabis in managing symptoms of late-stage dementia. This study, officially named the LiBBY Study, is backed by both the National Institutes of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later